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OBJECTIVE: To evaluate the association between the depth of trophoblastic infiltration and serum vascular
endothelial growth factorconcentration in patients with an ampullary pregnancy.
METHODS: This prospective cross-sectionalstudy involved 34 patients with an ampullary ectopic pregnancy who
underwent salpingectomy between 2012 and 2013. Maternal serum vascular endothelial growth factor
concentrations were measured using Luminex technology. Trophoblastic invasion was classified histologically as
follows: stage I, limited to the tubal mucosa; stage II, reaching the muscle layer; and stage III,involving the full
thickness. The qualitative data were compared using Fisher’s exact test. The nonparametric Kruskal-Wallis and
Mann-Whitney tests were used to evaluate differences in serum vascular endothelial growth factor among the
degrees of trophoblastic invasion. ROC curves were constructed to determine vascular endothelial growth
factor cut-off values that predict the degree of tubal invasion based on the best sensitivity and specificity.
RESULTS: Eight patients had stage I trophoblastic invasion, seven had stage II, and 19 had stage III. The median
serum vascular endothelial growth factorconcentration was 69.88 pg/mL for stage I, 14.53 pg/mL for stage II and
9.08 pg/mL for stage III, with a significant difference between stages I and III. Based on the ROC curve, a serum
vascular endothelial growth factor concentration of 25.9 pg/mL best differentiated stage I from stages II and III
with asensitivity of 75.0%, specificity of 76.9%, and area under the curve of 0.798.
CONCLUSIONS: The depth of trophoblastic penetration into the tubal wall isassociated with serum vascular
endothelial growth factor concentration in ampullary pregnancies.
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’ INTRODUCTION
Ectopic pregnancy (EP) is a form of anomalous pregnancy
in which the fertilized egg implants outside the uterine
cavity (1). The Fallopian tube is the most common site of
implantation (98%), but EP can also occur at other sites, such
as the ovaries, abdomen and broad ligament (2). EPs account
for 1-2% of all pregnancies, and hemorrhage due to tubal
rupture remains the most common cause of maternal mor-
tality in the first trimester of gestation (3). The increasing
incidence of EP is strongly associated with a greater
prevalence of late primiparity, pelvic inflammatory disease
and other sexually transmitted diseases, tubal sterilization
and subsequent attempted reversal, and cesarean section
delivery; a larger number of pregnancies conceived using
assisted reproductive technology; and the use of levonorges-
trel as an emergency contraceptive method (4-6).
Vascular endothelial growth factor (VEGF) is an angio-
genic factor that participates in the processes ofvascular
development in the embryo and implantation and placenta-
tion, in which it functions as animportant modulator of
vascular growth, remodeling and permeability in the deci-
dua, endometrium and trophoblast (7,8). Cellular production
of VEGF isaugmentedby tissue hypoxia (9,10); the implanta-
tion conditions in the tubesare very different from those in
the well-vascularized endometrium, and VEGF production
and secretion appear to be increased in EP (11,12).
The implantation of trophoblastic tissue into the tubal wall
can damage oviductal function by evoking an inflammatoryDOI: 10.6061/clinics/2016(12)04
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response that injures the cilia of the epithelium and disturbs
the architecture of the wall musculature, thus increasing the
risk for another episode of EP (13,14). The impairment of
tubal function depends on the degree of trophoblast invasion
into the wall of the uterine tubes. There are no adequate
standardsor methods for predicting the depth of tropho-
blastic invasion into the tubal wall. Serum concentrations of
beta-human chorionic gonadotropin (hCG) and the presence
of an embryo with a heartbeat can be used to estimate tro-
phoblastic invasion and damage to the histological structure
of the Fallopian tubes caused by trophoblastic implantation
(15-18). According to Cabar et al. (19), greater VEGF con-
centrations allow deeper invasion of trophoblastic tissue into
the tubes. These authors concluded that higher serum VEGF
levels are related to the discovery of an embryo with a
heartbeat by ultrasound. Higher VEGF production is likely
to create developmental conditions that are more favorable
for ectopic embryos (20).
The objective of this study was to evaluate the association
between the depth of trophoblastic infiltration into the tubal
wall and serum concentrations of VEGF in patients withan
ampullary pregnancy using a more sensitive method than
those used previously.
’ MATERIALS AND METHODS
Patients with an ampullary pregnancy who underwent a
salpingectomy between July 11, 2012, and August 19, 2013, were
included in this prospective study. The other inclusion criteria
were singleton pregnancy, spontaneous conception, a diagnosis
of tubal pregnancy in the ampullary portion and salpingectomy
as the treatment. The exclusion criteria were as follows: no
consensus regarding the location of the tubal pregnancy upon
surgical identification and histological analysis and inability to
measure serum VEGF on the day of surgery. Gestational age
was determined based on the last menstrual period.
Sixty-three consecutive cases of EP were documented
during the study period. Of these, 21 patients were not
included for different reasons: informed consent could not be
obtained from one patient, and the other 20 patients were
treated by a conservative approach (clinical or surgical).
Forty-two patients who met the inclusion criteria were
selected to participate in the study. Eight patients were
excluded: three because the tubal implantation site could
not be identified, two because no trophoblastic tissue was
detected by histological analysis, one because tissue VEGF
could not be identified, and two because blood collectionfor
serum VEGF measurement was not possible.
Routine measurements of serum beta-hCG and transvaginal
ultrasounds were performed to confirm the diagnosis. After
diagnostic confirmation, if the woman was eligible for inclusion
in the study, the serum VEGF concentration was determined.
Blood samples were collected by peripheral venous puncture
into siliconized tubes. After coagulation of the sample for
30 minutes, serum was separated from whole blood by centri-
fugation at 4500 rpm for 20 minutes at 4oC, divided into two
aliquots, and stored in a freezer at -70oC for later analysis.
The samples were analyzed in duplicate using the Bio-Plex
ProTM Human Cytokine 27-plex Assay according to the
manufacturer’sinstructions. The assays were carried out by
staff members who were unawareof the clinical condition of
each pregnant woman. The reactions were diluted 1:2 so that
the results were within the measurable range of the standard
curves of the kit. TheBio-Plexassay was performed to
simultaneously quantify multiple cytokines in plasma. The
Luminexassay uses a similar principle to that of sandwich
ELISA. Colored and fluorescent microspheres/beads were
coated with monoclonal antibodies against eight targetsand
added to the wells. Samples and standards (ranging from 0.1
to 10,000 pg/mL per analysis) were added to the wells and
the mixtures were incubated. Then, the wells were washed
and the washing solution was removed with a magnetic
washer in which the microspheres were magnetically retai-
ned (Bio-Plex Pro II Wash Station). After washing, a mixture
of the secondary biotinylated antibody was added and the
plates were incubated again. Streptavidin conjugated to a
fluorescent protein, R-phycoerythrin (streptavidin-RPE), was
added and the plates were incubated for a short period. After
a washing step to remove unbound reagent, buffer solution
(Luminex, MiraiBio, Alameda, CA) was added to the wells,
and the results were recorded (100 minutes to complete all
analyses) in a microsphere analyzer (Bio-Plex 200). The con-
centrations of the unknown samples (antigens in plasma
samples) were estimated from the standard curves using Bio-
Plex Manager Software (Bio-Rad Laboratories, Hercules,
CA). Cytokine levels are expressed as pg/mL.
The Fallopian tubes were fixed in 10% formalin and cut
into serial sections for light microscopy analysis. An average
of 10 hematoxylin-eosin-stained sections were analyzed.
Additionally, the histological material was stained with
Masson’s trichrome to detect muscle fibers in order to
facilitate the identification of tissue invaded by the tropho-
blast. Immunohistochemical staining for human placental
lactogen was performed to identify the intermediate tropho-
blast and to determine the depth of trophoblastic invasion
into the tubal wall. A single experienced pathologist who
was unaware of the clinical and laboratory characteristics of
the patients performed all the histological assessments.
Tubal pregnancies were classified histologically according
to the depth of trophoblastic infiltration into the tubal wall
(17): stage I, trophoblastic infiltration limited to the tubal
mucosa; stage II, trophoblastic infiltration extending to the
tubal muscularis; and stage III, complete tubal wall infiltra-
tion with or without rupture of the serosa.
To calculate the sample size, the study by Cabar et al. (19)
was considered as a reference for the effect size for the three
degrees of trophoblastic invasion. Therefore, when consider-
ing a significance level of 5% and a statistical power of 95%,
the calculated minimum sample size was 21 cases (G*Power
software, version 3.1.9.2).
The qualitative data are reported asthe absolute and relative
frequency (percentage), and these data were compared using
Fisher’s exact test. As a summary of the quantitative variables,
the median, minimum, maximum, mean, and standard devi-
ation were calculated. Nonparametric Kruskal-Wallis andMann-
Whitney tests were used to evaluate differences in serum
VEGFamong the degrees of trophoblastic invasion. ROC curves
were constructed to determine VEGF cut-off values that predict
the degree of tubal invasion based on the best sensitivity and
specificity. A p-valueo0.05 was considered to indicate statistical
significance. All tests were twotailed. The statistical analysis was
performed using SPSS Statistics 22.0 for Macintosh (IBM Corp.,
Armonk, NY).
Ethics
The Institutional Review Board (CAPPesq-Clinical
Research Ethics Committee of the University of São Paulo)
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approved the study. Informed consent was obtained from
each patient before inclusion.
’ RESULTS
Patient age ranged from 11 to 40 years (29.8±6.6 years),
andthere were no significant differences in mean maternal
age among the three histological groups (p=0.706). Twenty-
four (70.4%) patients were Caucasian, and 14 (29.4%) were
non-Caucasian. With respect to obstetric history, 18 (52.9%)
patients were nulliparous, and five (14.7%) had a history of
EP in the contralateral Fallopian tube. Histological analysis
showed that eight (23.5%) patients had stage I tubal infil-
tration, seven (20.6%) had stage II, and 19 (55.9%) had stage
III. The gestational age ranged from 28 to 95 days (53.2±14.5
days), and there were no significant differences in the mean
gestational ageamong the three histological groups (p=0.604).
Serum VEGF concentrations on the day of surgery ranged
from 0.036 to 205.16 pg/mL (median, 14.77 pg/mL).The
Kruskal-Wallis test revealed that at least one stage was
significantly different from the others (p=0.036) (Table 1).
Pairwise comparisons of VEGF concentration among the
three stages of trophoblastic invasion revealed a significant
difference between stage I and stage III (p=0.031); stage I
invasion was associated with higher median VEGF values
than those in stage III (Table 1). On the other hand, no
differences were found when patients with stage I vs. stage II
and stage II vs. III were compared, demonstrating that serum
VEGF can only differentiate patients at stage I from those at
stage III (Table 2).
As there was no significant difference between stage I and
stage II or between stage II and stage III, an analysis was
performed after grouping stages II and III (II+ III) or stages
I and II (I+II). The first comparison showed a significant
difference (p=0.010): stage I cases presented a higher median
serum VEGF concentration compared to stage II+ III cases.
On the other hand, the second comparison showed no signi-
ficant difference between stage III and stages I + II (p=0.05)
(Table 3). Based on the previous finding of a difference
only between stage I and stages II+ III, the ROC curve was
adjusted to obtain a cut-off concentration of VEGF that better
discriminated stage I from stages II + III, with better
sensitivity and specificity values. A serum VEGF level of
25.9 pg/mL best differentiated stage I from stages II +III,
with a sensitivity of 75.0%, specificity of 76.9%, and area
under the curveof 0.798.
’ DISCUSSION
The results revealed a difference in serum VEGF concentra-
tion between patients with stage I and stage III trophoblastic
invasion, with stage I cases presenting with a higher median
VEGF concentration than stage III cases. No differences were
found for stage I vs. stage II or for stage II vs. III; thus, serum
VEGF can only differentiate stages I and III. ROC curve
analysis showed that a serum VEGF level of 25.9 pg/mL best
differentiated stage I from stages II+ III, with a sensitivity of
75.0% and a specificity of 76.9%. A previous study from our
group demonstrated an increase in the depth of trophoblastic
penetration into the tubal wall with increasing maternal serum
VEGF concentration (19). We postulated that elevated cellular
production of VEGF permits deeper invasion of trophoblastic
tissue into the tubal wall. In the present study, we intended to
repeat the investigation using a more sensitive method for
measuring serum VEGF, namely, Luminextechnology, which
is similar in principle to sandwich ELISA.
Unexpectedly, serum VEGF concentrations decreased with
the depth of trophoblastic invasion into the tubal wall; lower
VEGF levels were observed in cases with deeper invasion.
A previous study with a similar population size reported that
a cut-off value of 297.2 pg/mL predicted stage I trophoblastic
invasion with 100% sensitivity and a negative predictive value
of 100%. Moreover, VEGF levels above 440.1 pg/mL predicted
stage III trophoblastic invasion. Considering the high sensi-
tivity, specificity and positive and negative predictive values,
higher serum VEGF levels seemed to be a good predictor of
deeper trophoblast invasion and consequently greater destruc-
tion of the tubal wall (19). Serum VEGF levels were higher in
cases of more superficial trophoblastic invasion. The findings
of the present study are different from those reported by Cabar
et al. (19), who showed a direct relationship between increased
serum VEGF and the depth of trophoblastic invasion into the
oviduct. We believe that the use of different methods for
determining serum VEGF levels may have contributed to the
differences between the studies.
Only ampullary pregnancies were included in this study
since they are the most common extrauterine site of tropho-
blastic implantation, accounting for more than 70% of all EPs
(21). Sincethe anatomical segments of the Fallopian tube
differ histologically, trophoblastic penetration may be differ-
ent in each tubal portion.
In the population studied, trophoblastic invasion was
limited to the mucosa in 23.5% of the patients, reached the
muscle layer in 20.6%, and penetrated the full thickness of
the tubal wall in the remaining 55.9%. Similar percentages
were reported by Cabar et al. (15) (27.6%, 28.6% and 43.8%,
respectively). The predominance of cases in which tropho-
blastic invasion reached at least the muscle layer (76.5%) is
consistent with previous studies (15,17,20).
Serum progesterone concentrations are increased in preg-
nancy and there is an important relationship between increases
in hCGand VEGF that contributes to trophoblastic invasion.
Evans et al. (10) stated that progesterone enhances VEGF
production in epithelial cells of the retina and that hCG
increases VEGF in granulosa cells. Since the serum levels of
progesterone and hCG are lower in EP, despite local hypoxia,
VEGF production may remain unchanged due to the nega-
tive effect of the decreases in these hormones.
Table 1 - Serum VEGF and depth of trophoblastic invasion.
Trophoblastic
invasion
Number of
patients
VEGF (pg/mL) Median
(range)
Stage I 8 69.88 (5.30–93.46)
Stage II 7 14.53 (0.36–68.16)
Stage III 19 9.08 (0.0–205.16)
p=0.036 (nonparametric Kruskal-Wallis test).
Table 2 - Pairwise comparison of the depth of trophoblastic
invasion.
Comparison p-value*
Stage I vs.stage II 0.310
Stage I vs.stage III 0.031
Stage II vs.stage III 0.990
*Nonparametric Kruskal-Wallis test.
701
CLINICS 2016;71(12):699-702 VEGF and trophoblastic invasion in tubal pregnancies
Cabar FR et el.
Previous studies have shown that estrogen increases VEGF
secretion in humans and animals (22,23). Similarly, reduc-
tions in the serum levels of estrogen, progesterone and
hCG, in addition to decreases in other cytokines and growth
factors with a yet unknown role in EP, may increase the
concentration of VEGF, albeit not to a significant degree due
to this counterbalancing effect.
In this study, we aimed to determine why trophoblastic
invasion encounters more favorable conditions and reaches
the deepest layers of the Fallopian tube in some cases. An
understanding of this process and its relationship with
possible predictors of trophoblastic invasion in the Fallopian
tubes, such as serum beta-hCG and ultrasound findings,
should contribute to the diagnosis and treatment of women
with EP. We decided to study serum concentrations because
we intended to provide information to clinicians that could
help them decide whether to remove Fallopian tubes affected
by EP (conservative or radical treatment).
Due to differences between the two existing studies on this
subject, we believe that additional studies with a larger
number of cases are necessary to completely clarify this issue.
We conclude that the depth of trophoblastic invasion
into the tubal wall is associated with maternal serum VEGF
concentration in women with ampullary EP. VEGF can dis-
criminate stage I from stage III cases in terms of penetration
depth.
Our results differ from those of previous studies, and
further investigation is needed to confirm our findings.
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